



Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017

Cambridge, UK, 30 November 2017 – Crescendo Biologics Ltd (Crescendo), a company developing highly potent and differentiated Humabody® therapeutics, with a proprietary pipeline of targeted T-cell Biologics, announces winning the “Licensing Deal of the Year” award at last night’s Scrip Awards 2017.

Crescendo won the award with Takeda Pharmaceutical Company Limited ([TSE: 4502](#)), for a commercial partnership signed in October 2016, worth up to US\$790 million. This transformational deal validated and further enhanced Crescendo’s capabilities for delivering novel, Humabody®-based therapeutics.

Using its proprietary transgenic platform and engineering expertise, Crescendo is discovering and developing highly targeted, exceptionally potent Humabody® therapies in the immuno-oncology field.

Dr. Peter Pack, CEO of Crescendo Biologics commented:

“We are extremely proud to have been recognised by the industry, winning “Licensing Deal of the Year” at this year’s Scrip awards, for our collaboration with Takeda. This also comes shortly after winning the European MediScience award as “Emerging Star of the Year”, adding to Crescendo’s successful year.

We have been able to build a strong partnership whilst working with the highly experienced and flexible Takeda team; their endorsement of our technology and our combined focus has allowed us to broaden and accelerate our Humabody® candidates, with the end goal of treating cancer more effectively.”

The 13th Annual Scrip Awards took place at The Hilton Park Lane in London last night and was well represented by a full range of industry experts, from big pharma and biotech companies, through to CROs. The Scrip Awards provides the industry with an opportunity to acknowledge its highest achievers across all parts of the value chain and to recognize both corporate and individual achievement.

Other finalists for the “Licensing Deal of the Year” category were AstraZeneca and Aspen, for ex-US rights to AZ’s global anaesthetics portfolio, as well as MedImmune and Allergan for MEDI2070. Other successes on the night included the “Pharma Company of the Year” award going to Celgene and Rolf Stahel receiving the “Lifetime Achievement Award”. The 2016 “Licensing Deal of the Year” award went to Galapagos and Gilead Sciences, for filgotinib in inflammatory diseases.

-Ends-

For more information, please contact:

**Crescendo Biologics
Dr Peter Pack, CEO**

**Tel:44 (0)1223 497140
info@crescendobiologics.com**

**Instinctif Partners
Dr Christelle Kerouedan / Melanie Toyne-Sewell**

**Tel:44 (0)20 7457 2020
crescendo@instinctif.com**



Notes to Editors

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody[®] therapeutics in oncology with an internal focus on biologics for Targeted T-cell Therapy with novel modes-of-action. It is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships in both multi-functional immuno-oncology modulators and Humabody[®] Drug Conjugates (HDCs), the next generation of ADCs.

The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V_H domain building blocks (Humabody[®] V_H) comprising the full structural diversity of the human V_H repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com

About Humabody[®] Therapeutics

Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human V_H domain building blocks (Humabody[®] V_H) isolated from heavy chain-only antibodies produced using Crescendo's proprietary transgenic mouse.

Compared with monoclonal antibodies, Humabodies[®] offer a unique combination of potential benefits resulting from their broad structural diversity, small size, high yield and robust biophysical properties. These attributes allow Crescendo to configure an almost limitless range of multi-specific and multi-functional Humabody[®] formats in a rapid timeframe.

Crescendo is developing a pipeline of novel, Humabody[®]-based therapeutics in oncology. Next-generation multi-specific Humabody[®] IO modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response as well as specific targeting of IO modulators into the tumor-microenvironment, enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment. Humabody[®] Drug Conjugates (HDCs) demonstrate a superior therapeutic index to standard ADCs.

For more information, please visit the website: www.crescendobiologics.com/humabody